Atorvastatin cuts heart risk but not disability-free survival

Summarised from 2 outlets · Updated 6 Oct, 09:01 · Archive

A trial found atorvastatin reduced cardiovascular event risk by 30% but did not significantly improve disability-free survival.

A trial published by the European Society of Cardiology has examined the effects of atorvastatin, a widely used medication. The study found that atorvastatin reduced major cardiovascular event risk by 30%.

However, the research also showed that whilst the drug improved cardiovascular outcomes, it did not significantly improve disability-free survival in trial participants. The findings provide a more nuanced picture of atorvastatin's benefits beyond its traditional cardiovascular protective effects.

How it is being reported

• Major update for anyone taking Atorvastatin after huge trialThe Mirror · 6 Oct, 08:35
• Major update for people taking common drug over ‘death risk’Daily Express · 4 Oct, 11:02

In this story: European Society of Cardiology · Atorvastatin

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem